Garching, July 30, 2024 — PreciPoint, a German-based leading medical technology startup and provider of advanced digital pathology and microscopy solutions, today announced its expansion in the United States. This strategic growth underscores PreciPoint’s commitment to delivering cutting-edge technologies and services to a broader market while fostering closer relationships with its American clientele.
The new U.S. entity, headquartered in Boston, will serve as a pivotal hub for PreciPoint’s operations in the American market. The expansion aims to enhance the company’s ability to provide end-to-end digital solutions, including its flagship products for digital pathology, to the growing demand in the region.
Focusing on key areas
“We are excited to begin this new chapter in PreciPoint’s journey,” says Nicolas Weiss, CEO of PreciPoint Group GmbH. “The U.S. represents a significant market with immense potential for growth in digital pathology. Our presence here will allow us to better support our existing customers and reach new ones, driving innovation and advancing the digitization of pathology labs, diagnostics, and research.”
With a dedicated team on the ground, PreciPoint will provide more immediate support to its American clients. This local presence ensures that customers receive optimal performance and satisfaction from PreciPoint’s products and services. The ability to offer timely and efficient support is expected to significantly enhance the customer experience and foster stronger client relationships.
Collaborated partnership
“Our goal is to transform the field of digital pathology and microscopy by providing state-of-the-art solutions that enable new work and business models enhancing diagnostic resources and research capabilities for better accuracy and improved patient care,” adds James Brown, Director of PreciPoint International Inc. “With our U.S. presence, we are well-positioned to significantly impact and drive progress in the medical and scientific fields.”
The U.S. team will work closely with local partners and stakeholders to expand market reach, increase brand awareness, and drive the adoption of PreciPoint’s digital pathology and microscopy solutions. By leveraging the expertise and networks of regional partners, PreciPoint aims to accelerate its growth and establish a prominent presence in the U.S. market.
Joining hands with Spectrum Healthcare Partners
PreciPoint intends to establish and strengthen partnerships with leading academic institutions, research organizations, and healthcare providers. One such collaboration is with Spectrum Healthcare Partners. The collaboration seamlessly integrates PreciPoint’s state-of-the-art imaging device with Spectrum Healthcare Partners’ network of certified pathologists. Pathologists can now view digital images of tissue sections in real-time, allowing them to analyze specimens remotely and provide immediate feedback and consultation.
“Spectrum Healthcare Partners is committed to delivering high-level patient care through innovation and collaboration,” stated Bilal R. Ahmad, MD, MBA, Chair of digital and computational pathology at Spectrum Healthcare Partners. “By partnering with PreciPoint, we are connecting technology to overcome barriers to healthcare access and improve decision-making. As a leading healthcare provider in the region, we recognize the potential of remote pathology processes. By joining forces with PreciPoint, we are driving innovation and ensuring equitable access to high-quality pathology services.”
About PreciPoint
PreciPoint Group GmbH is a leading international provider of solutions for the digitalization and automation of pathology laboratories. Based in Germany, the ISO 13485:2016-certified start-up develops, produces, and markets its highly innovative products and sells them worldwide. PreciPoint’s current flagship product is the IVD medical device iO:M8, which is used by pathologists for the intraoperative viewing of frozen sections during surgical procedures on cancer patients. Furthermore, PreciPoint is an international leader in the development of solutions using cutting-edge technologies for the label-free analysis (label-free diagnostics) of pathological images.